News

Reston, VA—A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy. By identifying this mutation early, physicians can tailor treatment plans for patients to achieve the best results.

New research from Memorial Sloan Kettering Cancer Center (MSK) developed CAR T cells that target two acute myeloid leukemia-specific antigens; shed new light on a genetic element called LINE-1, opening the door to new treatments; identified a key regulator of blood stem cell fate; and

A groundbreaking study led by Professor Sebyung Kang and Professor Sung Ho Park in the Department of Biological Sciences at UNIST has unveiled a remarkable breakthrough in cancer treatment. The research team has successfully developed unprecedented “NK cell-engaging nanodrones” capable of selectively targeting and eliminating

A research team, affiliated with UNIST has unveiled a novel method to produce a selective anticancer precursor substance that targets and eliminates cancer cells. This groundbreaking method, previously existing only in theory, has now been experimentally proven for the first time, opening up new possibilities in

“[…] the results of this preclinical investigation program suggest that induction of apoptosis is a key component of GFH009’s anti-tumor mechanism of action […]” Credit: 2023 Zhou et al. “[…] the results of this preclinical investigation program suggest that induction of apoptosis is a key

For patients with early-stage breast cancer, there is a 7% to 11% chance of relapse within five years after receiving initial treatment, and this rate can be higher for patients with more advanced stage of the cancer. While chemotherapy aims to eliminate all cancer cells,

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition. Credit: Asian Fund for Cancer Research Limited The Asian Fund for Cancer Research (AFCR) is pleased to announce that

A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine. Credit: Xiaohua Duan A drug screening system that models cancers using

Gastric cancer, a significant global health burden, claims over 7% of cancer-related deaths annually. Although only 1-3% of cases have a genetic basis, understanding these genetic drivers is crucial for developing preventative strategies. Credit: By Mokhtari-Esbuie F, Szeglin B, Rouhani Ravari M, et al. Gastric

Doctors diagnosed Christopher Gregg, Ph.D., member of the Nuclear Control of Cell Growth and Differentiation Program at Huntsman Cancer Institute at the University of Utah (the U) and neuroscientist and professor of neurobiology and human genetics at the U, with stage 4 metastatic breast cancer